NEW YORK, Aug. 17, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. (“4D” or the “Company”) (NASDAQ: FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether 4D and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 17, 2024, 4D announced what it described as “positive initial interim 24-week landmark data from the Population Extension cohort of the PRISM Phase 2 Clinical Trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population.” Notwithstanding the Company’s positive characterization of the trial results, analysts were quick to raise questions, noting among other things that certain features of the trial “complicate [the] results in a broader population despite prior efficacy signals in more severe patients.”
As investors reacted to the significance of the trial results, 4D’s stock price fell $11.61 per share, or 43.4%, over the following two trading sessions, to close at $15.14 per share on July 18, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
